Travere Therapeutics Email Format

Biotechnology
201-500 employees
San Diego, CA, USA

Travere Therapeutics is a biopharmaceutical company focused on identifying, developing, and delivering life-changing therapies for people living with rare diseases.

Find contacts at Travere Therapeutics

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@travere.com

Company Overview

Industry
Biotechnology
Founded
2020
Headquarters
San Diego, CA, USA
Revenue
$250M-$500M
FUNDING Stage
Public
Key Executives
Eric Dube, Ph.D. (President & Chief Executive Officer), Chris Cline, CFA (Chief Financial Officer), Peter Heerma (Chief Commercial Officer)

Tech Stack

Veeva

CRM

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Travere Therapeutics?

Travere Therapeutics uses the first.last format, so Jane Smith would be jane.smith@travere.com.

What approved products does Travere Therapeutics currently market?

Travere Therapeutics markets FILSPARI (sparsentan) for IgA Nephropathy and Focal Segmental Glomerulosclerosis, and Thiola EC and Thiola (tiopronin) for Cystinuria, making rare kidney and metabolic diseases the core of its commercial portfolio.

Where is Travere Therapeutics headquartered and how large is the company?

Travere Therapeutics is headquartered in San Diego, CA and has approximately 503 employees. Tools like Clay can help you find and verify the right contact at the company for outreach or prospecting purposes.

Who leads Travere Therapeutics as CEO in 2026?

Eric Dube, Ph.D. serves as President and Chief Executive Officer of Travere Therapeutics in 2026, with Chris Cline as Chief Financial Officer and Peter Heerma as Chief Commercial Officer rounding out the executive team.

What is Travere Therapeutics' pegtibatinase program targeting?

Pegtibatinase is Travere Therapeutics' investigational Phase 3 therapy for Classical Homocystinuria, a rare metabolic disease, being studied in the HARMONY pivotal trial.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles